Trial reportFrontiers in immunology2018
The Synergistic Effects of the Glutathione Precursor, NAC and First-Line Antibiotics in the Granulomatous Response Against
Trial report in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Clinical effects of N-acetylcysteine in ICU patients with respiratory disease: a systematic review and meta-analysis.Respiratory research & clinical practice · 2026Pooled it
- Pooled it
- Pooled it
- The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis.Respiratory research · 2020Pooled it
- The Effects of Oral Liposomal Glutathione and In Vitro Everolimus in Altering the Immune Responses againstBiomolecular concepts · 2021Trial
- Effects of Oral Liposomal Glutathione in Altering the Immune Responses AgainstFrontiers in cellular and infection microbiology · 2021Trial
- N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR).Frontiers in medicine · 2026Review
- Effects of Glutathione on Antibiotic Susceptibility and Resistance in Bacteria: A Comprehensive Review.Infection and drug resistance · 2026Review
- Additive Effects ofInternational journal of molecular sciences · 2025Article
- Inhalable N-Acetylcysteine-loaded Lactose-coated PLGA Nanoparticles for Tuberculosis Treatment.Pharmaceutical research · 2025Article
- Article
- Redox Biomarkers in Asymptomatic Latent Human Tuberculosis: A Comparison With Active Disease.The Journal of infectious diseases · 2024Article
- Immune Responses toBiomedicines · 2024Article
- The association between plasma free amino acids and type 2 diabetes mellitus complicated with infection in Chinese patients.Diabetology & metabolic syndrome · 2024Article
- An Update to Novel Therapeutic Options for Combating Tuberculosis: Challenges and Future Prospectives.Current pharmaceutical biotechnology · 2024Review
- Natural Compounds and Glutathione: Beyond Mere Antioxidants.Antioxidants (Basel, Switzerland) · 2023Review
- IL-21, Inflammatory Cytokines and Hyperpolarized CD8Antioxidants (Basel, Switzerland) · 2023Article
- Impact ofAntioxidants (Basel, Switzerland) · 2022Review
- Rare Mycobacteria and HIV in Children: Two Case Reports.Clinical drug investigation · 2022Article
- L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response toFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.